ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Randomized trials of surgery with and without adjuvant combination chemotherapy in resected gastric cancer

Randomized trials of surgery with and without adjuvant combination chemotherapy in resected gastric cancer
Author, year Country n Chemotherapy Hazard ratio for survival (95% CI)
Non-anthracycline-containing polychemotherapy
Huguier M; 1980 France 53 5-FU, VBL, CTX No significant survival difference
Schlag P; 1982 Germany 98 5-FU, BCNU 0.66 (0.31-1.41)
Douglass H; 1982 USA 142 5-FU, MeCCNU 0.58 (0.35-0.95)*
Ochiai T; 1983 Japan 59 MMC, 5-FU, Ara-C 1.08 (0.5-2.31)
Higgins G; 1983 USA 134 5-FU, MeCCNU 0.94 (0.58-1.53)
Engstrom P; 1985 USA 180 5-FU, MeCCNU 0.94 (0.58-1.53)
Jakesz R; 1988 Austria 87 Ara-C, MMC, 5-FU 0.65 (0.38-1.13)
Bonfanti G; 1988 Italy 144 5-FU, MeCCNU 0.97 (0.61-1.55)
Allum W; 1989 UK 271 MMC, 5-FU 0.99 (0.73-1.36)
Allum W; 1989 UK 270 CTX, 5-FU, VCR, MTX then MMC, 5-FU 1.01 (0.74-1.38)
Nakajima T; 1999 Japan 573 MMC, 5-FU, UFT 0.74 (0.5-1.09)
Cirera L; 1999 Spain 148 MMC, Ftorafur 0.60 (0.39-0.93)*
Nashimoto A; 2003 Japan 252 MMC, 5-FU, Ara-C No significant survival difference
Bang Y; 2012 Korea 1035 Capecitabine, oxaliplatin 0.72 (0.52-1.00)*
Anthracycline-containing polychemotherapy
Coombes R; 1990 UK 281 5-FU, DOX, MMC 0.89 (0.66-1.21)
Krook J; 1991 USA 125 5-FU, DOX 0.97 (0.62-1.51)
Hallissey M; 1994 UK 283 5-FU, DOX, MMC 0.95 (0.74-1.22)
Macdonald J; 1995 USA 193 5-FU, DOX, MMC 0.91 (0.65-1.28)
Lise M; 1995 Italy 294 5-FU, DOX, MMC 0.86 (0.64-1.14)
Tsavaris N; 1996 Greece 84 5-FU, EPI, MMC 0.76 (0.31-1.87)
Neri B; 1996 Italy 103 5-FU, LV, EPI 0.46 (0.27-0.77)*
Di Costanzo F; 2008 Italy 258 PELF 0.91 (0.64-1.26)
Bouche O; 2005 France 260 Infusional 5-FU, CIS 0.74 (0.54-1.02)
Nitti D; 2006 EORTC 206 5-FU, DOX, MTX 0.89 (0.51-1.31)Δ
Nitti D; 2006 ICCG 191 5-FU, EPI, MTX 1.05 (0.69-1.41)Δ
De Vita F; 2007 GOIM 228 5-FU, LV, EPI, ETOP 0.91 (0.69-1.21)
Kulig J; 2010 Poland 309 EAP 0.889 (0.676-1.169)
S-1 monotherapy
Sasako M; 2011 Japan 1059 S-1 0.67 (0.54-0.83)*
5-FU: fluorouracil; VBL: vinblastine; CTX: cyclophosphamide; BCNU: Carmustine; MeCCNU: Semustine (methyl-CCNU); MMC: mitomycin C; Ara-C: cytarabine; MTX: methotrexate; VCR: vincristine; UFT: ftorafur and uracil; DOX: doxorubicin; EPI: epirubicin; LV: leucovorin; PELF: cisplatin, epirubicin, leucovorin, 5-FU; CIS: cisplatin; EORTC: European Organization for Research and Treatment of Cancer; ICCG: International Collaborative Cancer Group; GOIM: Grupopa Oncologico dell'Italia Meridionale; ETOP: etoposide; EAP: etoposide, doxorubicin, cisplatin.
* Statistically significant values for survival.
¶ Induction chemotherapy with five days of CTX, 5-FU, VCR, and MTX, followed by MMC and 5-FU.
Δ Both trials reported together, neither of which reached its accrual goal (760 for the EORTC and 480 for the ICCG trials).
Graphic 71898 Version 10.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟